Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

Showing 1 to 4 of 4

TitleReference numberPublishedLast updated
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)TA609
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodineTA535
Sorafenib for treating advanced hepatocellular carcinomaTA474
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinomaTA178

Results per page

  1. 10
  2. 25
  3. 50
  4. All